The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Ramat Gan, Israel.
Sackler Faculty of Medicine, School of Public Health, Department of Epidemiology and Preventive Medicine, Tel Aviv University, Tel Aviv, Israel.
Diabetes Metab Res Rev. 2018 Sep;34(6):e3018. doi: 10.1002/dmrr.3018. Epub 2018 Jun 17.
Pancreatic cancer has an extremely highly case fatality. Diabetes is a well-established strong risk factor for pancreatic cancer. Compared with a nondiabetic population, we previously reported a 15- and 14-fold greater risk for detecting pancreatic cancer during the first year after diagnosing diabetes in adult women and men, respectively, which dropped during the second year to 5.4-fold and 3.5-fold, respectively, and stabilized around 3-fold for the rest of the 11-year follow-up in our historical cohort. The population attributable risk during the 11-year period was 13.3% and 14.1% in prevalent diabetic women and men, respectively. This means that one out of about every 8 patients diagnosed with pancreatic cancer has been previously diagnosed with diabetes. The globally high prevalence of diabetes and the aggravating implications of a delayed pancreatic cancer diagnosis call for newly-onset diabetes to be considered a potential marker for an underlying pancreatic cancer and addressed accordingly.
胰腺癌的病死率极高。糖尿病是胰腺癌的一个明确的强危险因素。与非糖尿病人群相比,我们之前报道过,在成年女性和男性中,糖尿病诊断后第一年分别有 15 倍和 14 倍更高的风险检测到胰腺癌,第二年风险分别降至 5.4 倍和 3.5 倍,在我们的历史队列中,随后的 11 年随访期间稳定在 3 倍左右。在 11 年期间,新诊断糖尿病女性和男性的人群归因风险分别为 13.3%和 14.1%。这意味着大约每 8 例被诊断为胰腺癌的患者中就有 1 例之前被诊断患有糖尿病。全球范围内糖尿病的高患病率和延迟诊断胰腺癌的严重后果表明,新发糖尿病应被视为潜在胰腺癌的一个潜在标志物,并进行相应处理。